Structure-based design of antibodies targeting the EBNA1 DNA-binding domain to block Epstein–Barr virus latent infection and tumor growth

Abstract

The Epstein–Barr virus (EBV) nuclear antigen 1 (EBNA1) is critically involved in maintaining episomes during latent infection and promoting tumorigenesis. The development of an epitope-specific monoclonal antibody (mAb) for EBNA1 holds great promise due to its high affinity and specificity, offering a new and innovative approach for the treatment of EBV-related diseases. In this proof-of-concept study, we employed a structure-based design strategy to create three unique immunogens specifically targeting the DNA binding state of the EBNA1 DBD. By immunizing mice, we successfully generated a mAb, named 5E2-12, which selectively targets the DNA binding interface of EBNA1. The 5E2-12 mAb effectively disrupts the interaction between EBNA1 and DNA binding, resulting in reduced proliferation of EBV-positive cells and inhibition of xenograft tumor growth in both cellular assays and mouse tumor models. These findings open up new avenues for the development of innovative biological macromolecular drugs that specifically target EBNA1 and provide potential for clinical therapy options for early-stage EBV-positive tumors. The epitope-specific mAb approach demonstrates novelty and innovation in tackling EBV-related diseases and may have broad implications for precision medicine strategies in the field of viral-associated cancers.

Keywords

Epstein–Barr virus latent infection / Epstein–Barr virus nuclear antigen 1 / monoclonal antibody / tumor

References

[1] Epstein A. Why and how Epstein-Barr virus was discovered 50 years ago. Curr Top Microbiol Immunol. 2015; 390(1): 3-15. Pt.

[2] Xu M, Feng R, Liu Z, et al. Host genetic variants, Epstein-Barr virus subtypes, and the risk of nasopharyngeal carcinoma: assessment of interaction and mediation. Cell Genom. 2024; 4(2): 100474.

[3] Feder HM Jr, Rezuke WN. Infectious mononucleosis diagnosed by Downey cells: sometimes the old ways are better. Lancet. 2020; 395(10219): 225.

[4] Schulze Lammers FC, Bonifacius A, Tischer-Zimmermann S, et al. Antiviral T-cell frequencies in a healthy population: reference values for evaluating antiviral immune cell profiles in immunocompromised patients. J Clin Immunol. 2022; 42(3): 546-558.

[5] Dheekollu J, Wiedmer A, Ayyanathan K, et al. Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance. Cell. 2021; 184(3): 643-654.

[6] Paludan SR, Bowie AG, Horan KA, et al. Recognition of herpesviruses by the innate immune system. Nat Rev Immunol. 2011; 11(2): 143-154.

[7] Giehler F, Ostertag MS, Sommermann T, et al. Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex. Nat Commun. 2024; 15(1): 414.

[8] Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023; 21(1): 51-64.

[9] Lanz TV, Brewer RC, Ho PP, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022; 603(7900): 321-327.

[10] Bonglack EN, Messinger JE, Cable JM, et al. Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas. Proc Natl Acad Sci USA. 2021; 118(25).

[11] Liang T, Chen H, Liu L, et al. Antibody profiling of pan-cancer viral proteome reveals biomarkers for nasopharyngeal carcinoma diagnosis and prognosis. Mol Cell Proteomics. 2024; 23: 100729.

[12] De Leo A, Calderon A, Lieberman PM. Control of viral latency by episome maintenance proteins. Trends Microbiol. 2020; 28(2): 150-162.

[13] Li JSZ, Abbasi A, Kim DH, et al. Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats. Nature. 2023; 616(7957): 504-509.

[14] Bochkarev A, Barwell JA, Pfuetzner RA, et al. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell. 1996; 84(5): 791-800.

[15] Deakyne JS, Malecka KA, Messick TE, et al. Structural and functional basis for an EBNA1 hexameric ring in Epstein-Barr virus episome maintenance. J Virol. 2017; 91(19): e01046-17.

[16] Messick TE, Smith GR, Soldan SS, et al. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth. Sci Transl Med. 2019; 11(482): eaau5612.

[17] Crescioli S, Kaplon H, Chenoweth A, et al. Antibodies to watch in 2024. MAbs. 2024; 16(1): 2297450.

[18] Weitz JI, Tankó LB, Floege J, et al. Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial. Nat Med. 2024; 30(2): 435-442.

[19] Shin SM, Choi DK, Jung K, et al. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. Nat Commun. 2017; 8: 15090.

[20] Wen Y, Waltman A, Han H, et al. Switching the immunogenicity of peptide assemblies using surface properties. ACS Nano. 2016; 10(10): 9274-9286.

[21] Xu K, Acharya P, Kong R, et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat Med. 2018; 24(6): 857-867.

[22] Li N, Thompson S, Schultz DC, et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS ONE. 2010; 5(4): e10126.

[23] Krishnamurthy S, Wohlford-Lenane C, Kandimalla S, et al. Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia. Nat Commun. 2019; 10(1): 4906.

[24] Strong MJ, Baddoo M, Nanbo A, et al. Comprehensive high-throughput RNA sequencing analysis reveals contamination of multiple nasopharyngeal carcinoma cell lines with HeLa cell genomes. J Virol. 2014; 88(18): 10696-10704.

[25] Syn NL, Lim PL, Kong LR, et al. Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models. Signal Transduct Target Ther. 2018; 3: 9.

[26] Lee AW, Ng WT, Chan YH, et al. The battle against nasopharyngeal cancer. Radiother Oncol. 2012; 104(3): 272-278.

[27] Jakhmola S, Jonniya NA, Sk MF, et al. Identification of potential inhibitors against Epstein-Barr virus nuclear antigen 1 (EBNA1): an insight from docking and molecular dynamic simulations. ACS Chem Neurosci. 2021; 12(16): 3060-3072.

[28] Jiang L, Lan R, Huang T, et al. EBNA1-targeted probe for the imaging and growth inhibition of tumours associated with the Epstein–Barr virus. Nat Biomed Eng. 2017; 1(4): 0042.

[29] Soldan SS, Anderson EM, Frase DM, et al. EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer. Gastric Cancer. 2021; 24(5): 1076-1088.

[30] Jiang L, Lung HL, Huang T, et al. Reactivation of Epstein-Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn(2+)-chelating function. Proc Natl Acad Sci USA. 2019; 116(52): 26614-26624.

[31] Jiang L, Xie C, Lung HL, et al. EBNA1-targeted inhibitors: novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics. 2018; 8(19): 5307-5319.

[32] Boike L, Cioffi AG, Majewski FC, et al. Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC. Cell Chem Biol. 2021; 28(1): 4-13.e17.

[33] Mun SS, Meyerberg J, Peraro L, et al. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunol Immunother. 2023; 72(11): 3773-3786.

[34] Zhao Y, Jiang H, Yu J, et al. Engineered histidine-rich peptides enhance endosomal escape for antibody-targeted intracellular delivery of functional proteins. Angew Chem Int Ed Engl. 2023; 62(38): e202304692.

[35] Zhao Y, Gan L, Ke D, et al. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy. J Transl Med. 2023; 21(1): 693.

[36] Ma YH, Hong X, Wu F, et al. Inhibiting the transcription and replication of Ebola viruses by disrupting the nucleoprotein and VP30 protein interaction with small molecules. Acta Pharmacol Sin. 2023; 44(7): 1487-1499.

[37] Chen X, Huang Y, Gao P, et al. Engineering of novel hemagglutinin biosensors for rapid detection and drug screening of Influenza A H7N9 virus. Int J Biol Macromol. 2024; 258(2): 129126. Pt.

[38] Shi LF, Ren H, Zhang B, et al. Preparation and epitope mapping of monoclonal antibodies against African swine fever virus p22 protein. Int J Biol Macromol. 2024; 255: 128111.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.